Table 1.
Cohort demographics
| Non-CF (n=20) | Infants with CF (NCH, n=15) | Infants with CF (validation, n=20) | Children with CF (NCH, n=42) | CF P value* | |
|---|---|---|---|---|---|
| Age (years) | 12.9±13.4 | 0.37±0.05 | 0.41±0.17 | 5.2±2.6 | <0.001* |
| Sex (% female) | 60.0 | 60.0 | 50 | 47.6 | 0.33 |
| Pancreatic insufficiency | n/a | 86.7% | 95% | 95.2% | 0.70 |
| Genotype | |||||
| Phe508del homozygous | n/a | 40.0% | 45% | 47.6% | 0.13 |
| Phe508del heterozygous | n/a | 53.3% | 50% | 42.9% | 0.97 |
| FEV0.5/FEV1 % predicted | n/a | 101.4±11.8 | 97.2±13.9 | 95.6±16.3 | 0.54 |
| Hx Pseudomonas aeruginosa | n/a | 33.3% | 20% | 54.8% | 0.026* |
| Hx MRSA | n/a | 20.0% | 10% | 30.9% | 0.18 |
| Hair nicotine | |||||
| Detected | 73.3% | 40% | 61.9% | 0.11 | |
| Median ng/mg (25%-75% IQR) | 24.9 (0.8–39.4) | n/a | 1.7 (0.1–5.5) | 0.011* |
SHSe is associated with AA dysregulation in CF. Nicotine concentrations for the infant with CF validation cohort were run in a separate batch at a later date with updated standards, and therefore did not have comparable values for presentation.
*
P values for comparisons between CF groups only, via one-way analysis of variance for all comparisons except t-test for median nicotine.
AA, arachidonic acid; CF, cystic fibrosis; Hx, history; MRSA, methicillin-resistant Staphylococcus aureus; n/a, not available; NCH, Nationwide Children’s Hospital; SHSe, secondhand smoke exposure.